Breaking News

Rosa & Co. Acquires Entelos Service Business

By Kristin Brooks | January 23, 2014

Expands presence in systems pharmacology market

Rosa & Co. LLC, a drug development consulting firm, has acquired the consulting service business of Entelos Holdings, Inc., which conducts mechanistic, physiologic, in silico modeling projects for customers for pharmaceutical research and development. The acquisition expands Rosa's presence in quantitative systems pharmacology and modeling and simulation research services and adds expertise in cardiovascular, immunology, and metabolism biology, and human nutrition.
 
The acquisition also allows Entelos' clients to access Rosa's PhysioPD Research Platforms, which employ a user-friendly, open-architecture modeling and simulation system that is interoperable with commonly used third-party software.
 
"We are thrilled to further strengthen our expertise in these key areas, and have the opportunity to offer our proven approach to an expanded client base,” said chief executive officer of Rosa, Ron Beaver, Ph.D."
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer